Our Team

Soren has worked extensively in the Biotech space for >20 years and has helped secure over $2M in federal awards from NIH.  Throughout his tenure at TopoGEN his roles have included grants AOR, comptroller, laboratory manager, sales and procurements director, and finally Chief Operating Officer.  Early in his career, while TopoGEN was still in start-up mode at the BTC incubator at Ohio State, Soren learned the importance of developing synergies with affiliated outfits in biomedicine. 

His passion for mountain biking and snowboarding has not waned over the years, which brought an interest in hemp therapeutics into focus for him as an alternative to more traditional forms of pain and muscle relief.   Ultimately his goal in joining CBxGEN is the refinement of newer, healthier forms of pain management coupled with ongoing human disease research. 

Mr. Rief started in the CBD industry in 2016 by starting a hemp farm in Southeast Colorado. His farm was one of the first USDA organic-approved hemp farms in the United States.  He used his extensive background in midwest agriculture and engineering education to maximize the operation.  

Jerame and Dr. Muller met in college when Jerame was enrolled in one of Dr. Muller’s classes and their synergies matched and had similar goals and ambitions to start CBD research in Colorado.  By joining forces between TopoGEN, Inc. and CBx Genomics & Therapeutics, a strong science-based synergy was created in the collaboration. 

Rick Rabon received his medical degree from the University of Colorado School of Medicine and completed his medical residency in family medicine through the University of Tennessee Graduate School of Medicine. Dr. Rabon was recognized as one of the top physician researchers from his residency program for his work studying botanicals as safe alternatives to toxic synthetic surface antiseptics used in the hospital setting.

Dr. Rabon has been involved in scientific and clinical medical research since prior to entering medical school and has authorship in multiple peer reviewed journals. Much of his research was focused on Duchenne Muscular Dystrophy and ameliorating the debilitating effects of this disease, which included the use of natural dietary supplements. Dr. Rabon began to take an interest in the therapeutic potential of hemp in his clinical practice, but recognized the lack of rigorous scientific studies behind these products. Subsequently, in 2021 Dr. Rabon joined forces with Dr. Muller and his team at TopoGEN as a research consultant assisting them in elucidating potential biomarkers and therapeutic targets for Alzheimer’s disease. Techniques that were applied in this research fueled a drive to begin exploring how different molecular compounds extracted and isolated from hemp alter the human genome through epigenetic modifications and related gene expression. Dr. Rabon is able to continue this research through a partnership with CBx Genomics & Therapeutics, where he also serves as a medical and scientific advisor in product development.